DK1140969T3 - Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf - Google Patents

Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf

Info

Publication number: DK1140969T3
Authority: DK; Denmark
Prior art keywords: methods; ctgf; growth factor; connective tissue; tissue growth
Prior art date: 1998-12-14

Application number

DK99965256T

Other languages

Danish (da)

English (en)

Inventor

Gary R Grotendorst

Original Assignee

Univ Miami

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-14

Filing date

1999-12-14

Publication date

2007-09-17

1999-12-14 Application filed by Univ Miami filed Critical Univ Miami

2007-09-17 Application granted granted Critical

2007-09-17 Publication of DK1140969T3 publication Critical patent/DK1140969T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Zoology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)

DK99965256T 1998-12-14 1999-12-14 Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf DK1140969T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11224098P	1998-12-14	1998-12-14
US11224198P	1998-12-14	1998-12-14
PCT/US1999/029652 WO2000035936A1 (en)	1998-12-14	1999-12-14	Connective tissue growth factor fragments and methods and uses thereof

Publications (1)

Publication Number	Publication Date
DK1140969T3 true DK1140969T3 (da)	2007-09-17

Family

ID=26809725

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99965256T DK1140969T3 (da)	1998-12-14	1999-12-14	Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf

Country Status (16)

Country	Link
US (3)	US6492129B1 (zh)
EP (2)	EP1140964B1 (zh)
JP (2)	JP4722290B2 (zh)
KR (2)	KR100664626B1 (zh)
CN (3)	CN1660911A (zh)
AT (2)	ATE391724T1 (zh)
AU (3)	AU773278B2 (zh)
CA (2)	CA2354422A1 (zh)
CY (1)	CY1108860T1 (zh)
DE (2)	DE69936315T2 (zh)
DK (1)	DK1140969T3 (zh)
ES (2)	ES2304811T3 (zh)
HK (2)	HK1041268B (zh)
MX (1)	MXPA01005949A (zh)
PT (1)	PT1140969E (zh)
WO (2)	WO2000035939A2 (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0804562B1 (en)	1994-07-12	2002-10-09	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US7026299B2 (en)	1994-07-12	2006-04-11	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US7115390B1 (en) *	1998-12-14	2006-10-03	Fibrogen, Inc.	Connective tissue growth factor fragments and methods and uses thereof
ATE391724T1 (de) *	1998-12-14	2008-04-15	Univ Miami	FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
CA2412124A1 (en) *	2000-07-11	2002-01-17	Haodong Li	Connective tissue growth factor-2
AU2002326939A1 (en) *	2001-09-18	2003-04-01	Fibrogen, Inc.	Methods of assaying connective tissue growth factor
WO2003035083A1 (de) *	2001-10-26	2003-05-01	Ribopharma Ag	Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
US6965025B2 (en)	2001-12-10	2005-11-15	Isis Pharmaceuticals, Inc.	Antisense modulation of connective tissue growth factor expression
AU2002366641A1 (en) *	2001-12-11	2003-06-23	Fibrogen, Inc.	Methods for inhibiting ocular processes
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7405274B2 (en)	2003-06-04	2008-07-29	Fibrogen, Inc.	Connective tissue growth factor antibodies
WO2005033136A1 (en) *	2003-09-29	2005-04-14	Children's Hospital, Inc.	Unique integrin binding site in connective tissue growth factor (ctgf)
US8258105B2 (en)	2003-10-07	2012-09-04	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides optimized for kidney targeting
US20050191653A1 (en)	2003-11-03	2005-09-01	Freier Susan M.	Modulation of SGLT2 expression
GB0326778D0 (en) *	2003-11-18	2003-12-24	Imp College Innovations Ltd	Biological materials and uses thereof
PL1715890T3 (pl)	2004-02-11	2009-01-30	Fibrogen Inc	CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
ZA200607588B (en) *	2004-02-11	2008-05-28	Fibrogen Inc	CTGF as target for the therapy of diabetic nephropathy
US20050271670A1 (en) *	2004-04-28	2005-12-08	Spong Suzanne M	Treatments for cancer
WO2005116194A1 (ja) *	2004-05-25	2005-12-08	Riken	試験管内筋繊維形成のための筋芽細胞又は筋芽細胞様細胞培養法
EP1692935A1 (en) *	2005-02-22	2006-08-23	Boehringer Ingelheim International GmbH	Transgenic animal as a model for human pulmonary disease
MX2007013819A (es)	2005-05-05	2008-02-05	Fibrogen Inc	Terapias de enfermedades cardiovasculares.
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
ES2453941T5 (es)	2005-11-30	2017-05-31	Abbvie Inc.	Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
WO2008027288A2 (en)	2006-08-30	2008-03-06	The Trustees Of Columbia University In The City Of New York	Treatment for craniosynostosis by growth factor delivery
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8617877B2 (en) *	2007-11-02	2013-12-31	The Johns Hopkins University	Cardiac stem cell and myocyte secreted paracrine factors
US8946172B2 (en)	2008-08-25	2015-02-03	Excaliard Pharmaceuticals, Inc.	Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010042281A2 (en)	2008-08-25	2010-04-15	Excaliard Pharmaceuticals	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2010027830A2 (en) *	2008-08-25	2010-03-11	Excaliard Pharmaceuticals, Inc.	Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
EP2340309A2 (en)	2008-09-22	2011-07-06	Rxi Pharmaceuticals Corporation	Neutral nanotransporters
WO2011002525A1 (en)	2009-07-02	2011-01-06	Fibrogen, Inc.	Methods for treatment of muscular dystrophy
US20120244169A1 (en)	2009-11-06	2012-09-27	Fibrogen, Inc.	Treatment for Radiation-Induced Disorders
CA2794187C (en)	2010-03-24	2020-07-14	Rxi Pharmaceuticals Corporation	Rna interference in ocular indications
KR20180044433A (ko)	2010-03-24	2018-05-02	알엑스아이 파마슈티칼스 코포레이션	진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
KR101249041B1 (ko) *	2010-04-28	2013-03-29	포항공과대학교 산학협력단	결합조직 성장인자를 이용한 약학적 조성물
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
US20140134181A1 (en)	2010-11-05	2014-05-15	Kenneth E. Lipson	Treatment Method For Lung Remodeling Diseases
US9102721B2 (en)	2011-01-21	2015-08-11	Fibrogen, Inc.	Therapeutic method
BR112013019803A2 (pt)	2011-02-02	2019-06-11	Excaliard Pharmaceuticals Inc	método de tratar quelóides ou cicatrizes hipertróficas usando os compostos anti-sentido objetivando fator de desenvolvimento de tecido conjuntivo (ctgf)
BR112014015405A2 (pt) *	2011-12-22	2017-06-13	Astellas Pharma Inc	novo anticorpo ctgf anti-humano
US9480449B2 (en)	2012-05-03	2016-11-01	Fibrogen, Inc.	Methods for treating idiopathic pulmonary fibrosis
US9132171B2 (en)	2012-05-23	2015-09-15	Wisconsin Alumni Research Foundation	Test of insulin as a drug to reduce restenosis of vessels
US9631013B2 (en)	2014-01-28	2017-04-25	Fibrogen, Inc.	Therapeutic method for pancreatic cancer
WO2016205226A1 (en)	2015-06-15	2016-12-22	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosing and treating affective disorders
CN109402127B (zh) *	2018-09-29	2021-12-10	复旦大学附属眼耳鼻喉科医院	一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN111424035A (zh) *	2020-04-13	2020-07-17	西南大学	基于家蚕丝腺表达具有生物学活性的人结缔组织生长因子的方法及其产品和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US392024A (en) *		1888-10-30		Jjett
US4906742A (en) *	1986-07-31	1990-03-06	Whitehead Institute For Biomedical Research	Encoding antigens of M. Leprae
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5071773A (en) *	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
FR2678283A1 (fr) *	1991-06-25	1992-12-31	Centre Nat Rech Scient	Sequences de nucleotides, sequences d'acides amines correspondantes, et leurs applications biologiques.
US5408040A (en) *	1991-08-30	1995-04-18	University Of South Florida	Connective tissue growth factor(CTGF)
US5770209A (en) *	1991-08-30	1998-06-23	University Of South Florida	Acceleration of wound healing using connective tissue growth factor
US5474796A (en) *	1991-09-04	1995-12-12	Protogene Laboratories, Inc.	Method and apparatus for conducting an array of chemical reactions on a support surface
ES2136092T3 (es) *	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5877289A (en) *	1992-03-05	1999-03-02	The Scripps Research Institute	Tissue factor compositions and ligands for the specific coagulation of vasculature
US5596090A (en) *	1992-07-24	1997-01-21	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human VCAM-1 RNA
EP0804562B1 (en)	1994-07-12	2002-10-09	Human Genome Sciences, Inc.	Connective tissue growth factor-2
US5789389A (en) *	1995-03-17	1998-08-04	Board Of Trustees Of University Of Illinois	BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5688915A (en)	1995-06-01	1997-11-18	The University Of Medicine And Dentistry Of New Jersey	Long term maintenance of lymphocytes in vitro
EP0871705A4 (en) *	1995-06-05	2000-01-26	Human Genome Sciences Inc	CCN TYPE HUMAN GROWTH FACTOR
EP0827742A1 (en) *	1996-09-04	1998-03-11	Vrije Universiteit Brussel	Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
US5876730A (en) *	1997-08-07	1999-03-02	Childrens Hospital Research Foundation	Heparin-binding growth factor (HBGF) polypeptides
EP1043335A4 (en) *	1997-12-25	2005-08-31	Japan Tobacco Inc	MONOCLONAL ANTIBODY AGAINST THE BIND WEIGHT GROWTH FACTOR AND ITS MEDICAL USES
AU2870399A (en) *	1998-02-20	1999-09-06	Zymogenetics Inc.	Connective tissue growth factor homologs
US6238921B1 (en) *	1998-03-26	2001-05-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of human mdm2 expression
US6348329B1 (en) *	1998-11-06	2002-02-19	Fibrogen, Inc.	Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
ATE391724T1 (de) *	1998-12-14	2008-04-15	Univ Miami	FRAGMENT DES ßCONNECTIVE TISSUE GROWTH FACTORß (CTGF)
US7405274B2 (en) *	2003-06-04	2008-07-29	Fibrogen, Inc.	Connective tissue growth factor antibodies

1999
- 1999-12-14 AT AT99966224T patent/ATE391724T1/de not_active IP Right Cessation
- 1999-12-14 CA CA002354422A patent/CA2354422A1/en not_active Abandoned
- 1999-12-14 CN CN2004101024245A patent/CN1660911A/zh active Pending
- 1999-12-14 KR KR1020017007410A patent/KR100664626B1/ko active IP Right Grant
- 1999-12-14 CN CNB99815850XA patent/CN1170849C/zh not_active Expired - Lifetime
- 1999-12-14 AT AT99965256T patent/ATE364617T1/de active
- 1999-12-14 PT PT99965256T patent/PT1140969E/pt unknown
- 1999-12-14 CA CA002354456A patent/CA2354456A1/en not_active Abandoned
- 1999-12-14 JP JP2000588194A patent/JP4722290B2/ja not_active Expired - Lifetime
- 1999-12-14 KR KR1020017007367A patent/KR100664625B1/ko active IP Right Grant
- 1999-12-14 WO PCT/US1999/029654 patent/WO2000035939A2/en active IP Right Grant
- 1999-12-14 MX MXPA01005949A patent/MXPA01005949A/es unknown
- 1999-12-14 WO PCT/US1999/029652 patent/WO2000035936A1/en active IP Right Grant
- 1999-12-14 EP EP99966224A patent/EP1140964B1/en not_active Expired - Lifetime
- 1999-12-14 DE DE69936315T patent/DE69936315T2/de not_active Expired - Lifetime
- 1999-12-14 CN CNB998158747A patent/CN1187370C/zh not_active Expired - Lifetime
- 1999-12-14 ES ES99966224T patent/ES2304811T3/es not_active Expired - Lifetime
- 1999-12-14 JP JP2000588197A patent/JP4634614B2/ja not_active Expired - Fee Related
- 1999-12-14 DK DK99965256T patent/DK1140969T3/da active
- 1999-12-14 EP EP99965256A patent/EP1140969B1/en not_active Expired - Lifetime
- 1999-12-14 AU AU31211/00A patent/AU773278B2/en not_active Expired
- 1999-12-14 DE DE69938507T patent/DE69938507T2/de not_active Expired - Lifetime
- 1999-12-14 US US09/461,688 patent/US6492129B1/en not_active Expired - Lifetime
- 1999-12-14 ES ES99965256T patent/ES2288321T3/es not_active Expired - Lifetime
- 1999-12-14 AU AU21819/00A patent/AU775391B2/en not_active Expired
2002
- 2002-04-09 HK HK02102627.5A patent/HK1041268B/zh not_active IP Right Cessation
- 2002-04-10 HK HK02102721.0A patent/HK1041005B/zh not_active IP Right Cessation
- 2002-12-09 US US10/315,568 patent/US7718177B2/en not_active Expired - Lifetime
2004
- 2004-08-20 AU AU2004205171A patent/AU2004205171B2/en not_active Expired
2007
- 2007-07-31 CY CY20071101018T patent/CY1108860T1/el unknown
2010
- 2010-04-06 US US12/755,367 patent/US20100190838A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1041005B (zh)	2007-11-09
ATE364617T1 (de)	2007-07-15
WO2000035939A3 (en)	2000-10-12
JP4634614B2 (ja)	2011-02-16
MXPA01005949A (es)	2002-09-18
EP1140964A4 (en)	2003-06-18
HK1041268B (zh)	2009-02-27
ATE391724T1 (de)	2008-04-15
AU2004205171A1 (en)	2004-09-16
JP4722290B2 (ja)	2011-07-13
EP1140969A1 (en)	2001-10-10
US20030180300A1 (en)	2003-09-25
CN1334820A (zh)	2002-02-06
AU775391B2 (en)	2004-07-29
KR20010101207A (ko)	2001-11-14
CN1334819A (zh)	2002-02-06
JP2002532084A (ja)	2002-10-02
HK1041005A1 (en)	2002-06-28
AU2004205171B2 (en)	2007-08-09
AU773278B2 (en)	2004-05-20
CY1108860T1 (el)	2014-07-02
US20100190838A1 (en)	2010-07-29
ES2288321T3 (es)	2008-01-01
EP1140964A2 (en)	2001-10-10
JP2002532082A (ja)	2002-10-02
KR20010101194A (ko)	2001-11-14
DE69938507D1 (en)	2008-05-21
KR100664626B1 (ko)	2007-01-04
CA2354422A1 (en)	2000-06-22
CN1170849C (zh)	2004-10-13
CN1660911A (zh)	2005-08-31
EP1140969B1 (en)	2007-06-13
WO2000035939A2 (en)	2000-06-22
EP1140964B1 (en)	2008-04-09
DE69936315T2 (de)	2008-02-14
ES2304811T3 (es)	2008-10-16
KR100664625B1 (ko)	2007-01-04
CN1187370C (zh)	2005-02-02
DE69938507T2 (de)	2009-06-10
CA2354456A1 (en)	2000-06-22
PT1140969E (pt)	2007-08-30
HK1041268A1 (en)	2002-07-05
EP1140969A4 (en)	2003-07-23
WO2000035936A1 (en)	2000-06-22
DE69936315D1 (de)	2007-07-26
US7718177B2 (en)	2010-05-18
US6492129B1 (en)	2002-12-10
AU3121100A (en)	2000-07-03
AU2181900A (en)	2000-07-03

Publication	Publication Date	Title
DK1140969T3 (da)	2007-09-17	Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
DE69839815D1 (de)	2008-09-11	Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE60042137D1 (de)	2009-06-10	Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
CA2213533A1 (en)	1996-08-29	Resorbable extracellular matrix for reconstruction of cartilage tissue
EA200200755A1 (ru)	2002-12-26	Опосредованная рецептором nogo блокада роста аксонов
ES2113857T3 (es)	1998-05-16	Composiciones osteoinductoras.
DE69914726D1 (de)	2004-03-18	Zusammensetzung zur regulierung des hauterscheinungsbildes
HUP9603484A2 (hu)	1998-05-28	Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
CA2265508A1 (en)	1998-03-26	Bone morphogenetic protein-16 (bmp-16) compositions
ATE202706T1 (de)	2001-07-15	Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE69634748D1 (de)	2005-06-23	Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
CY1111912T1 (el)	2015-11-04	Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
EP2228389A3 (en)	2010-12-01	Antibodies against vascular endothelial growth factor 2
FR2706767B1 (zh)	1995-09-08
DE69631478D1 (de)	2004-03-11	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
EA200401341A1 (ru)	2005-06-30	Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
ATE459644T1 (de)	2010-03-15	Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
EP1978362A3 (en)	2009-02-11	Cross beta structure comprising amyloid binding proteins and methods for detection of the cross beta structure, for modulating cross beta structures fibril formation and for modulating cross beta structure-mediated toxicity
DE69711078D1 (de)	2002-04-18	Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
TR199802271T2 (xx)	2000-08-21	s-CD23 �retiminin ve TNF salg�lanmas�n�n inhibit�rleri.
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
TR200200278T2 (tr)	2002-06-21	Kalsilitik bileşimler
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60232733D1 (de)	2009-08-06	Alternativ gesplicter zirkulierender gewebefaktor
ATE275964T1 (de)	2004-10-15	Verwendung von betalycan zur verminderung der narbenbildung